Now Available for Public Comment: Notice of Proposed Rulemaking (NPRM) for FDAAA 801 and NIH Draft Reporting Policy for NIH-Funded Trials

Effects of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection

This study has been completed.
Sponsor:
Collaborator:
Janssen Korea, Ltd., Korea
Information provided by (Responsible Party):
Myung-gui Choi, The Catholic University of Korea
ClinicalTrials.gov Identifier:
NCT00844675
First received: February 13, 2009
Last updated: October 16, 2012
Last verified: October 2012
  Purpose

The purpose of this study is:

  • To examine if oral administration of Pariet (proton pump inhibitor, 20mg tablets, twice daily for 5 days) before Endoscopic mucosal resection(EMR) exhibits preventive effects of ulcer bleeding compared with placebo group (preoperative administration of placebo)
  • To evaluate the effects on the suppression of acid secretion of preoperative administration of an Proton pump inhibitor

Condition Intervention Phase
Early Gastric Adenocarcinoma
Adenocarcinoma, Tubular
Drug: rabeprazole
Drug: placebo
Phase 4

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Double Blind (Subject, Caregiver, Investigator)
Primary Purpose: Prevention
Official Title: Effects of Preoperative Administration of Oral Rabeprazole on the Prevention of Ulcer Bleeding Following Endoscopic Mucosal Resection(EMR): Prospective, Randomized, Placebo-controlled, Comparative Study

Resource links provided by NLM:


Further study details as provided by The Catholic University of Korea:

Primary Outcome Measures:
  • Frequency of bleeding after EMR is performed [ Time Frame: 4weeks ] [ Designated as safety issue: Yes ]

Secondary Outcome Measures:
  • Number (No./cm2) of visible vessels on the fundus of ulcer on endoscopy performed within 24 hours after EMR [ Time Frame: day 1 ] [ Designated as safety issue: Yes ]
  • Percentage of a pH change with intragastric pH greater than 6 in 24 hours after EMR [ Time Frame: day 0 ] [ Designated as safety issue: No ]
  • Measurement of a change in the size of ulcer [ Time Frame: 4weeks ] [ Designated as safety issue: Yes ]

Enrollment: 120
Study Start Date: October 2007
Study Completion Date: March 2012
Primary Completion Date: December 2011 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: rabeprazole
rabeprazole
Drug: rabeprazole
The rabeprazole group will receive oral rabeprazole 20mg twice day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
Other Name: Pariet(rabeprazole)
Experimental: placebo
placebo
Drug: placebo
The placebo group will receive a placebo by mouth twice a day (morning and evening) 30 minutes before meals from 5 days before EMR (D-5) to 1 day before EMR (D-1).
Other Name: placebo

Detailed Description:
  • Endoscopic mucosal resection (EMR) is less invasive than surgery and is known to be general treatment for early gastric cancer or gastric adenoma when patients' quality of life is taken into consideration. However, major complications such as bleeding and perforation remain to be problematic.1-5 The incidence of these complications is expected to rise as the size of lesions for which EMR is indicated has enlarged. Histamine 2 receptor antagonists (H2RA) and proton pump inhibitors (PPI) have been used for the bleeding,1-3 but the bleeding rate following EMR has been reported to be still high as 1.4% to 24%.1,4 Green et al and Berstad et al cited in their research that intragastric PH should be sustained above 5.4 to prevent bleeding, and PPIs should be administered instead of H2RAs to keep PH above 5.4. Being studied are administration modalities to enhance the therapeutic efficacy of PPIs or H2RAs.1-3 Several studies have already demonstrated that high-dose PPI therapy, for which a PPI was administered twice daily, effectively blocks acid secretion by increasing intragastric pH to neutral.3 Our study team also suggested in a previous study that high-dose PPI therapy was adequate to maintain intragastric pH above 6.
  • PPIs are known to induce the suppression of acid secretion because they destroy a proton pump, yet it takes 5 days to achieve their maximum effects.7,8 It's been suggested that the onset of PPIs is slow to prevent bleeding with administration of a PPI after EMR.4 Therefore, our investigators expect that 5-day administration of an oral PPI before EMR would increase intragastric pH to above 6 and would be at least equal to or superior to intravenous PPIs currently being used in terms of the suppression of acid secretion.
  • This is a prospective, randomized, comparative study to substantiate that oral administration of rabeprazole (Pariet tablets) 20mg twice daily before and after EMR (PO RBP group) will show similar effects on the prevention of bleeding compared with the conventional treatment with iv administration of pantoprazole after EMR but no special medication given before EMR (Placebo group). In addition, we are going to measure intragastric pH among part of study subjects and then to evaluate if the effect of acid suppression in the PO RBP group is superior to that in the placebo group.
  Eligibility

Ages Eligible for Study:   18 Years to 70 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Patients who have EMR planned as well as meet the criteria described below will be selected as study subjects
  • Patients in whom EMR is indicated:

    1. Gastric adenoma
    2. Early gastric adenocarcinoma

      • Moderately or well differentiated adenocarcinoma
      • Gastric cancer limited to only mucosa on endoscopic ultrasonography
      • No invasion of lymph nodes or metastases (diagnosed by CT)
    3. EMR to be performed for other diagnostic purposes
  • Women of child-bearing potential should avoid pregnancy
  • Subjects who consented to a EMR procedure in writing

Exclusion Criteria:

  • Patients who meet the criteria described below should be excluded from study subjects:

    1. Younger than 18 years old
    2. Patients with a history of upper gastrointestinal surgery or vagotomy
    3. Patients with serious adverse reactions secondary to cardiac, renal, hepatic, or hematologic diseases (e.g. creatinine> 2.5 mg/dl, total bilirubin >3.0 mg/dl)
    4. Patients with diseases that may have a great impact on the clinical study
    5. Patients to whom the stimulation of gastrointestinal movement poses risks as in gastrointestinal bleeding, mechanical ileus and perforation
    6. Women who are pregnant or nursing
    7. Patients who are being treated with adrenocorticoid steroids, nonsteroidal anti-inflammatory drugs including aspirin, or other ulcer inducers
    8. Patients who are taking other antiulcer drugs (antacids, antihistamines, etc) that may affect the efficacy assessments of the study drug (but, except for patients not taking the drugs over 7 days)
    9. Patients with severe psychiatric diseases
    10. Patients who received other investigational drugs within 30 days prior to the start of this study or who are currently participating in other clinical study
    11. Patients who did not consent to the clinical study
    12. Patients who can not be examined
  • Patients with bleeding tendency
  • Patients with esophageal varices
  • Patients with esophageal ulcer, stricture, or obstruction
  • Patients who have pacemaker or implantable cardiac defibrillator in place
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00844675

Locations
Korea, Republic of
Catholic University, Gangnam St. Mary's Hospital
Seoul, Ban-po dong 505, Korea, Republic of, 137-040
Sponsors and Collaborators
The Catholic University of Korea
Janssen Korea, Ltd., Korea
Investigators
Principal Investigator: MyungKu Choi, MD The Catholic University of Korea
  More Information

No publications provided

Responsible Party: Myung-gui Choi, MD, PhD, The Catholic University of Korea
ClinicalTrials.gov Identifier: NCT00844675     History of Changes
Other Study ID Numbers: RAB-KOR-9035
Study First Received: February 13, 2009
Last Updated: October 16, 2012
Health Authority: South Korea: Korea Food and Drug Administration (KFDA)

Keywords provided by The Catholic University of Korea:
endoscopic mucosal resection
Proton Pump Inhibitor
gastrointestinal hemorrhage
rabeprazole

Additional relevant MeSH terms:
Adenocarcinoma
Carcinoma
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Glandular and Epithelial
Rabeprazole
Anti-Ulcer Agents
Enzyme Inhibitors
Gastrointestinal Agents
Molecular Mechanisms of Pharmacological Action
Pharmacologic Actions
Proton Pump Inhibitors
Therapeutic Uses

ClinicalTrials.gov processed this record on November 20, 2014